<DOC>
	<DOCNO>NCT01533207</DOCNO>
	<brief_summary>This randomized phase III trial study well gemcitabine hydrochloride docetaxel follow doxorubicin hydrochloride work compare observation treat patient high-risk uterine leiomyosarcoma previously remove surgery . Drugs use chemotherapy , gemcitabine hydrochloride , docetaxel , doxorubicin hydrochloride , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . It yet know whether combination therapy surgery effective treatment uterine leiomyosarcoma .</brief_summary>
	<brief_title>Gemcitabine Hydrochloride Docetaxel Followed Doxorubicin Hydrochloride Observation Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether overall survival patient uterus-limited high-grade leiomyosarcoma superior among patient assign treatment adjuvant gemcitabine hydrochloride plus docetaxel follow doxorubicin hydrochloride compare patient assigned observation . SECONDARY OBJECTIVES : I . To determine whether treatment adjuvant gemcitabine plus docetaxel follow doxorubicin improves recurrence-free survival patient uterus-limited high-grade leiomyosarcoma compare observation . II . To explore impact potential predictor recurrence death patient age , institution-reported tumor size , cervix involvement ( yes ) , mitotic rate . ( exploratory ) OUTLINE : Patients randomize 1 2 treatment arm . Arm I : Patients receive adjuvant gemcitabine hydrochloride IV 70-90 minute day 1 8 docetaxel IV 30-60 minute day 8 . Patients also receive filgrastim subcutaneously ( SC ) day 9-15 pegfilgrastim SC day 9 10 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients undergo compute tomography ( CT ) and/or magnetic resonance imaging ( MRI ) . Patients evidence disease receive doxorubicin hydrochloride IV every 21 day 4 course absence disease progression unacceptable toxicity . Patients also receive filgrastim SC day 2-8 pegfilgrastim SC day 2 3 . Arm II : Patients undergo clinical observation . After completion study treatment , patient arm follow every 4 month 3 year every 6 month 2 year .</detailed_description>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients highrisk uterine leiomyosarcoma ( LMS ) , International Federation Gynecology Obstetrics ( FIGO ) stage I ( confine corpus +/ cervix ) ; patient know uterine serosa involvement eligible ; patient , least , complete hysterectomy ( include removal cervix ) ; bilateral salpingooophorectomy ( BSO ) require Institutional pathology review call uterine leiomyosarcoma `` high grade '' Additionally , pathology report indicate mitotic rate , mitotic rate great equal 5 mitoses/10 highpower field All patient must longer 12 week ( 3 month ) surgical resection cancer time enrollment study ; patient require second operation complete surgery , i.e. , trachelectomy remove cervix and/or BSO , 12 week may count time second operation Patients `` morcellation '' hysterectomy procedure involve morcellation within peritoneal cavity eligible IF second operation perform biopsy second procedure show evidence leiomyosarcoma All patient must evidence persistent metastatic disease document postresection compute tomography ( CT ) chest/abdomen/pelvis CT chest + magnetic resonance imaging ( MRI ) abdomen/pelvis ; postresection image study perform within 4 week registration study Absolute neutrophil count ( ANC ) great equal 1,500/mcL ( ANC &gt; = 1.5 x 10^9/L ) Platelets great equal 100,000/mcL ( platelet &gt; = 100 x 10^9/L ) Hemoglobin great 8.0 g/dL ( = 80 g/L 4.9 mmol/L ) Creatinine le equal 1.5 x institutional upper limit normal ( ULN ) Bilirubin* within normal range Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) * serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) * less equal 2.5 time ULN Alkaline phosphatase* less equal 2.5 x ULN * Patients history Gilbert 's syndrome may eligible provided total bilirubin less equal 1.5 x ULN AST , ALT , alkaline phosphatase meet criterion detail Neuropathy ( sensory motor ) less equal Common Terminology Criteria Adverse Events ( CTCAE ) grade 1 Patients Gynecologic Oncology Group ( GOG ) performance status ( PS ) 0 1 OR Eastern Cooperative Oncology Group ( ECOG ) PS 0 1 OR Karnofsky PS &gt; = 80 % Patients meet preentry requirement specify Patients must sign approve informed consent Patients participate U.S. site must sign approved authorization permit release personal health information Patients free active infection require antibiotic ( exception uncomplicated urinary tract infection [ UTI ] ) Patients prior therapy docetaxel , gemcitabine hydrochloride , doxorubicin hydrochloride time history Patients history invasive malignancy , exception nonmelanoma skin cancer , ineligible evidence malignancy present within last five year Patients ineligible previous cancer treatment contraindicate protocol therapy Patients history severe hypersensitivity reaction Taxotere ( docetaxel ) drug formulate polysorbate 80 Patients GOG performance status 2 , 3 4 ; ECOG performance status 2 , 3 4 Patients breastfeeding Patients know history congestive heart failure cardiac ejection fraction &lt; 50 % ( less institutional normal limit ) ; echocardiogram ( ECHO ) multigated acquisition scan ( MUGA ) require prior enrollment ; patient assign chemotherapy arm , ECHO MUGA do within 6 month day 1 gemcitabinedocetaxel treatment Patients enroll study randomize Regimen I ( chemotherapy ) find baseline ECHO MUGA cardiac ejection fraction &lt; 50 % institutional normal remain ON study ; patient receive gemcitabine + docetaxel 4 cycle NOT receive doxorubicin treatment ; continue treatment followup outline patient assigned Regimen I Patients history whole pelvic radiation Concurrent treatment hormone replacement therapy permit discretion treat physician ; patient take hormonal/hormoneblocking agent breast cancer breast cancer prevention indication eligible ; use antihormonal agent ( tamoxifen , medroxyprogesterone , aromatase inhibitor ) permit discretion treat physician Patients recurrent uterine LMS Patients know human immunodeficiency virus ( HIV ) positive eligible Patients gross residual metastatic tumor finding follow complete surgical treatment uterine LMS</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>